RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      SCOPUS KCI등재

      분화성갑상선암에서 최초 고용량 방사성요오드 치료시 혈청 갑상선글로불린 수치 변화의 의의 = Value of the Serum Thyroglobulin Level Alteration at the First High Dose Radioiodine Treatment in Patients with Differentiated Thyroid Carcinoma

      한글로보기

      https://www.riss.kr/link?id=A76550918

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Purpose: The purpose of this study was to evaluate if short-term serum thyroglobulin (Tg) elevation after radioiodine administration can predict successful radioiodine remnant ablation (RRA) and whether comparable RRA effectiveness is exhibited between a group administered with recombinant human thyrotropin (rhTSH) and a group experiencing thyroid hormone withdrawal (THW), in preparation for RRA. Materials and Methods: A retrospective chart review was performed on 39 patients in the rhTSH group and 46 patients in the THW group. They were treated for differentiated thyroid carcinoma by total or near total thyroidectomy, and referred for RRA between 2003 and 2006 (the rhTSH group) and between January and June of 2006 (the THW group). They were assessed for serum Tg levels just before I-131 administration (TgD0), reassessed 9 days later (TgD9), and again 6-12 months later. Results: RRA was successful in 64 (37 from the THW group and 27 from the rhTSH group) of the total 85 patients. The success rates of RRA had no statistically significant differences between the two groups. In both groups, TgD9/TgD0 values were significantly higher in the RRA success group (the rhTSH group; P=0.03, the THW group; P=0.04). By combining cutoff values of TgD0 and TgD9/TgD0, the successful RRA value was determined to be 96.7% (29/30) with TgD0≤5.28 ng/mL and TgD9/TgD0>4.37 in both groups (the rhTSH group; 100% (16/16), the THW group; 92.9% (13/14)). Using logistic multivariate analysis, only TgD0 was independently associated with successful RRA. Conclusion: We may predict successful ablation by evaluating short-term serum Tg elevation after I-131 administration for RRA, in both rhTSH and THW patients. (Nucl Med Mol Imaging 2009;43(4):294-300)
      번역하기

      Purpose: The purpose of this study was to evaluate if short-term serum thyroglobulin (Tg) elevation after radioiodine administration can predict successful radioiodine remnant ablation (RRA) and whether comparable RRA effectiveness is exhibited betwee...

      Purpose: The purpose of this study was to evaluate if short-term serum thyroglobulin (Tg) elevation after radioiodine administration can predict successful radioiodine remnant ablation (RRA) and whether comparable RRA effectiveness is exhibited between a group administered with recombinant human thyrotropin (rhTSH) and a group experiencing thyroid hormone withdrawal (THW), in preparation for RRA. Materials and Methods: A retrospective chart review was performed on 39 patients in the rhTSH group and 46 patients in the THW group. They were treated for differentiated thyroid carcinoma by total or near total thyroidectomy, and referred for RRA between 2003 and 2006 (the rhTSH group) and between January and June of 2006 (the THW group). They were assessed for serum Tg levels just before I-131 administration (TgD0), reassessed 9 days later (TgD9), and again 6-12 months later. Results: RRA was successful in 64 (37 from the THW group and 27 from the rhTSH group) of the total 85 patients. The success rates of RRA had no statistically significant differences between the two groups. In both groups, TgD9/TgD0 values were significantly higher in the RRA success group (the rhTSH group; P=0.03, the THW group; P=0.04). By combining cutoff values of TgD0 and TgD9/TgD0, the successful RRA value was determined to be 96.7% (29/30) with TgD0≤5.28 ng/mL and TgD9/TgD0>4.37 in both groups (the rhTSH group; 100% (16/16), the THW group; 92.9% (13/14)). Using logistic multivariate analysis, only TgD0 was independently associated with successful RRA. Conclusion: We may predict successful ablation by evaluating short-term serum Tg elevation after I-131 administration for RRA, in both rhTSH and THW patients. (Nucl Med Mol Imaging 2009;43(4):294-300)

      더보기

      참고문헌 (Reference)

      1 Menzel C, "rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131I" 44 : 1065-1068, 2003

      2 Ronga G, "Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma" 26 : 1448-1452, 1999

      3 Giovanella L, "Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures" 44 : 648-652, 2006

      4 Torrens J, "Serum thyroglobulin measurement: Utility in clinical practice" 30 : 1-34, 2001

      5 Tuttle RM, "Recombinant-human TSH-assisted radioactive iodine remnant ablation achieves short term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal" 49 : 764-770, 2008

      6 Cramp WA, "Recent developments in the radiobiology of cellular membranes" 33 : 945-952, 1994

      7 Sweeney DC, "Radioiodine therapy for thyroid cancer" 24 : 803-839, 1995

      8 Pacini F, "Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study" 91 : 926-932, 2006

      9 Crevenna R, "Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxin supplementation therapy" 11 : 597-603, 2003

      10 Dow KH, "Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy" 7 : 613-619, 1997

      1 Menzel C, "rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131I" 44 : 1065-1068, 2003

      2 Ronga G, "Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma" 26 : 1448-1452, 1999

      3 Giovanella L, "Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures" 44 : 648-652, 2006

      4 Torrens J, "Serum thyroglobulin measurement: Utility in clinical practice" 30 : 1-34, 2001

      5 Tuttle RM, "Recombinant-human TSH-assisted radioactive iodine remnant ablation achieves short term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal" 49 : 764-770, 2008

      6 Cramp WA, "Recent developments in the radiobiology of cellular membranes" 33 : 945-952, 1994

      7 Sweeney DC, "Radioiodine therapy for thyroid cancer" 24 : 803-839, 1995

      8 Pacini F, "Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study" 91 : 926-932, 2006

      9 Crevenna R, "Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxin supplementation therapy" 11 : 597-603, 2003

      10 Dow KH, "Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy" 7 : 613-619, 1997

      11 Botella-Carretero JI, "Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma" 10 : 601-610, 2003

      12 Lima N, "Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer" 25 : 110-115, 2002

      13 Bernier MO, "Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer" 32 : 1418-1421, 2005

      14 Lee HJ, "Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma" 30 : 63-68, 2007

      15 Toubeau M, "Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer" 45 : 988-994, 2004

      16 Arslan N, "Post-surgical ablation of thyroid remnants with high-dose 131I in patients with differentiated thyroid carcinoma" 22 : 1021-1027, 2001

      17 Sugino K, "Management of differentiated thyroid carcinoma with radioiodine and recombinant human TSH" 53 : 723-728, 2006

      18 Karam M, "Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates" 24 : 489-495, 2003

      19 Luster M, "Guidelines for radioiodine therapy of differentiated thyroid cancer" 35 : 1941-1959, 2008

      20 Schlumberger M, "Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice" 151 : 539-548, 2004

      21 Rosario PW, "Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 <1 ng/ml determined by traditional assays?" 68 : 338-342, 2008

      22 Sawka AM, "Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer" 89 : 3668-3676, 2004

      23 Robbins RJ, "Clinical review 156: recombinant human thyrotropin and thyroid cancer management" 88 : 1933-1938, 2003

      24 Mazzaferri EL, "Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer" 86 : 1447-1463, 2001

      25 Mazzaferri EL, "An overview of the management of papillary and follicular thyroid carcinoma" 9 : 421-427, 1999

      26 Schroeder PR, "A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal" 91 : 878-894, 2006

      더보기

      동일학술지(권/호) 다른 논문

      동일학술지 더보기

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2016-12-26 학술지명변경 한글명 : Nuclear Medicine and Molecular Imaging -> Nuclear Medicine and Molecular Imaging
      외국어명 : 미등록 -> Nuclear Medicine and Molecular Imaging
      KCI등재
      2011-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2010-03-12 학술지명변경 한글명 : 핵의학 분자영상 -> Nuclear Medicine and Molecular Imaging KCI등재
      2009-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2007-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2005-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2002-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      1999-07-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.06 0.06 0.06
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.09 0.08 0.275 0
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼